Related Experiment Video

Updated: May 25, 2026

Ex Vivo Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics
08:29

Ex Vivo Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics

Published on: October 2, 2014

Oncogenic MST1R activity in pancreatic and gastric cancer represents a valid target of HSP90 inhibitors

Christian Moser1, Sven A Lang, Christina Hackl

  • 1Department of Surgery, University of Regensburg Medical Center, Franz-Josef-Strauss-Allee 11, 93053 Regensburg, Germany. christian.moser@ukr.de

Anticancer Research
|January 31, 2012
PubMed
Abstract

Insights

HSP90 blockade with EC154 effectively inhibits gastric and pancreatic cancer growth by targeting the MST1R receptor tyrosine kinase. This approach down-regulates MST1R expression and disrupts cancer cell signaling and migration.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Therapeutics

Background:

  • The macrophage-stimulating 1 receptor (MST1R) is an oncogenic receptor tyrosine kinase implicated in gastric and pancreatic cancers.
  • HSP90 is a molecular chaperone that stabilizes client proteins, including potentially MST1R, in cancer cells.

Purpose of the Study:

  • To investigate the therapeutic potential of blocking HSP90 with EC154 against MST1R in gastric and pancreatic cancer.
  • To elucidate the molecular mechanisms by which EC154 affects MST1R signaling, cancer cell behavior, and tumor growth.

Main Methods:

  • Western blotting was used to assess signaling pathway modulation by EC154.
  • Cancer cell migration was quantified using Boyden chambers.
  • Promoter-luciferase reporter assays examined transcriptional regulation of MST1R.
  • In vivo tumor models were employed to evaluate MST1R expression and tumor growth inhibition.

Main Results:

  • EC154 treatment effectively inhibited cancer cell growth and significantly reduced tumor growth in vivo.
  • EC154 down-regulated MST1R expression and diminished its promoter activity.
  • The drug disrupted oncogenic macrophage-stimulating protein 1 (MSP1) signaling and inhibited cancer cell migration.
  • Wild-type MST1R was identified as an HSP90 client protein in these cancer types.

Conclusions:

  • HSP90 inhibition represents a viable therapeutic strategy for targeting MST1R in gastrointestinal cancers.
  • EC154 demonstrates efficacy in preclinical models by targeting the MST1R-HSP90 interaction.
  • Further investigation into HSP90 inhibitors for MST1R-driven cancers is warranted.

More Related Videos

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA (lncRNA)...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...